Innovative new drugs have improved outcomes for many cancer patients. However, spending on cancer drugs has increased dramatically in recent years, far outpacing growth in spending on other components of cancer care. Rising drug costs are a burden on cancer patients and are straining health system and societal resources. In this report, the President’s Cancer Panel presents recommendations for ensuring alignment of drug prices with their value, promoting use of high-value drugs, and supporting continued innovation in cancer drug development.
Promote value-based pricing and use
Enable communication about treatment options and costs
Minimize contributions of drug costs to financial toxicity
Stimulate generic and biosimilar market competition
Ensure adequate resources for FDA
Invest in biomedical research